The ABTA–Metastatic Brain Tumor Collaborative CNS Metastasis Research Grants 2027 support early-career faculty investigating new approaches to diagnosing and treating cancer that has spread to the central nervous system. Awards provide $50,000 for one year to advance promising early-stage research. American Brain Tumor Association
The program covers brain metastases and leptomeningeal disease. A distinctive requirement is that projects must address metastases originating from at least two different primary organ sites, encouraging discoveries relevant across cancer types.
Eligibility Criteria
- Applicants must hold an MD, PhD, DrPH, DO, or equivalent doctorate.
- Applicants must hold a full-time faculty position, with no full-time faculty appointment before September 1, 2020. Documented leave adjustments require eligibility review.
- Lead institutions must be US-based nonprofit organisations; governmental institutions are ineligible.
- US citizenship or residency is not required.
- Projects must include CNS metastases from at least two distinct primary organ sites.
- A patient advocate must be named at the LOI stage and meaningfully involved throughout the project.
- Only one LOI per principal investigator is permitted per cycle.
Funding Details
- Award: US $50,000.
- Duration: One year.
- Supports salary and research expenses.
- Indirect costs may comprise up to 10%, within the total award.
Deadline
- Mandatory LOI: November 3, 2026, at noon CST, as stated in the RFA.
- Invited full applications: Around March 2, 2027.
- Earliest start: August 1, 2027.
Further Information
- Official program page
- 2027 Request for Applications
- Apply through ProposalCentral
- Contact: grants@abta.org